Medical oncology

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; AGED; BLADDER TUMOR; COLORECTAL TUMOR; FEMALE; HUMAN; LUNG TUMOR; METHODOLOGY; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY TUMOR; REVIEW;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; OVARIAN NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0035495374     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80028-9     Document Type: Article

References (17)

1. Von Hoff AD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91: 710-717.
2. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced brast cancer: the elimination of age trends in toxicity by using doses based on creatinin clearance. Clin Oncol 1984, 2: 1404-1413.
3. Sorio R, Robieux I, Galligioni E et al. Short communication, pharmacokinetics and tolerance of vinorlbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997, 33: 301-303.
4. Carlos RW, Goldstein LJ, Gradishar WJ et al. NCCN breast cancer practice guidelines. Oncology 1996, 10: 47-75.
5. Balducci L, Exterman M, Fentiman I, Monfardini S, Perrone F. Current controversy in cancer, should adjuvant chemotherapy be used to treat breast cancer in elderly patients (≥70 years of age)? Eur J Cancer 1997, 33: 1720-1724.
6. Gridelli C, Perrone F, Gallo C et al. On the behalf of ELVIS Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999, 91: 66-92.
7. Grunenberg SM, Bibawi SE. Lung cancer In: Hunter CP, Johnson KA, Muss HB (Eds), Cancer in the Elderly. New York, Basel, Marcel Dekker, 2000, pp. 345-360.
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggresive non Hodgkin's lymphoma. N Engl J Med 1993, 329(14): 887-994.
9. Monfardini S, Carbone A. Non Hodgkin's lymphoma. In: Balducci L, Lyman GH, Ershler (Eds.), Comprehensive Geriatric Oncology. Australia, Harwood, 1998, pp. 577-594.
10. Parmar MKB, Torti V, Bonaventura A et al. ICON 2: randomized trial of single agent carboplatin against three drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet 1998, 352: 1571-1576.
11. Cornelison TL, Reed E. Dose intensity of high dose carboplatin in refractory ovarian carcinoma relative to age. Cancer 1993, 71: 650-655.
12. Bicher A, Sarosy G, Kohn E et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993, 71: 594-600.
13. Pazdur R, Zinner R, Rothenberg ML et al. Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 1997, 16: 26.
14. Brower M, Asbury R, Kramer Z et al. Adjuvant chemotherapy for colorectal cancer in the elderly: population based experience. Proc Ann J Clin Oncol 1995, 12: 195.
15. Kerr DJ, Gray R, McConkey, Barnwell J. For Quasar Colorectal Cancer Study Group. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non randomized comparison of weekly versus four-weekly schedules - less pain sane gain. Ann Oncol 2000, 11: 947-955.
16. Sella A, LogothetiS CJ, Dexeus FH et al. Cisplatin combination chemotherapy for elderly patients with urotelial tumors. Br J Urol 1991, 67: 603-607.
17. Von Dermaase H, Hansen SW, Robert JT et al. Gemcitabine and cis-platinum versus methotrexate, vinblastine, doxorubicine and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter phase III study. J Clin Oncol 2000, 18: 3068.